

# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road,  
Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150

Fax: 00 91 (22) 2202 4657 E-mail: [info@amphray.com](mailto:info@amphray.com)

Website: [www.triochemproducts.com](http://www.triochemproducts.com) Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 2021625 2021; 14<sup>th</sup> August 2021

To  
BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers, Dalal Street,  
Fort, Mumbai: 400 001.  
Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Submission of Unaudited Financial Results for the Quarter ended 30<sup>th</sup> June 2021

We refer to our letter dated 6<sup>th</sup> August 2021 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Saturday, 14<sup>th</sup> August, 2021 have inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2021 duly reviewed by the Audit Committee.

The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report are enclosed for your perusal and records.

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in your record.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA  
DIRECTOR & CEO

DIN: 00312369

Encl.: as above



**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")**

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("Company")** for the quarter ended June 30, 2021 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
2. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP  
Chartered Accountants  
Firm Registration No: 104746W/W100096

KUNAL SUMANT  
VAKHARIA

Digitally signed by KUNAL  
SUMANT VAKHARIA  
Date: 2021.08.14 14:44:08  
+05'30'

Kunal Vakharia  
Partner  
Membership No.: 148916  
UDIN: 21148916AAAFZ2977

Place: Mumbai  
Date: 14<sup>th</sup> August 2021





**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

 Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001.

Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mail: info@amphray.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021					
(Rs. in lakhs) Except EPS					
Sr No	Particulars	Quarter Ended			Year Ended
		30-06-2021	31-03-2021	30-06-2020	31-03-2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income</b>				
	(a) Revenue from Operations	-	773.48	-	1,393.84
	(b) Other income	18.19	7.54	1.30	13.38
	<b>Total Income from operations</b>	<b>18.19</b>	<b>781.02</b>	<b>1.30</b>	<b>1,407.22</b>
2	<b>Expenses:</b>				
	(a) Cost of materials consumed	-	0.33	418.48	644.87
	(b) Purchase of stock-in-trade	-	602.73	-	602.73
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	-	125.29	(424.31)	13.41
	(d) Employee benefits expenses	11.50	16.39	16.89	66.91
	(e) Finance costs	0.38	1.37	2.09	10.90
	(f) Depreciation and amortisation expense	2.95	3.54	3.42	13.88
	(g) Other expenses	18.56	37.41	20.04	112.64
	<b>Total Expenses</b>	<b>33.39</b>	<b>787.06</b>	<b>36.61</b>	<b>1,465.33</b>
3	<b>Profit / (Loss) from ordinary activities before exceptional items (1-2)</b>	<b>(15.21)</b>	<b>(6.04)</b>	<b>(35.31)</b>	<b>(58.11)</b>
4	Exceptional items	-	-	-	-
5	<b>Profit / (Loss) before tax (3 +/- 4)</b>	<b>(15.21)</b>	<b>(6.04)</b>	<b>(35.31)</b>	<b>(58.11)</b>
6	<b>Tax expense</b>				
	- Current tax	(0.22)	(0.77)	0.02	(0.75)
	- Deferred tax	(4.06)	0.32	(8.83)	(12.66)
	<b>Total Tax expenses</b>	<b>(4.28)</b>	<b>(0.45)</b>	<b>(8.81)</b>	<b>(13.41)</b>
7	<b>Profit / (Loss) for the period (5 +/- 6)</b>	<b>(10.93)</b>	<b>(5.59)</b>	<b>(26.50)</b>	<b>(44.70)</b>
8	<b>Other comprehensive income, net of income tax</b>				
	A. (i) Items that will be reclassified to profit or Loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will not be reclassified to profit or Loss	1.68	(1.82)	0.11	(2.34)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.42)	0.46	(0.03)	0.59
	<b>Total Other comprehensive income, net of income tax</b>	<b>1.26</b>	<b>(1.36)</b>	<b>0.09</b>	<b>(1.75)</b>
9	<b>Total Comprehensive income for the period (8 +/- 7)</b>	<b>(9.67)</b>	<b>(6.95)</b>	<b>(26.42)</b>	<b>(46.45)</b>
10	<b>Paid-up equity share capital (Face value of Rs10/- per share )</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				1,146.69
12	<b>Earning per share (EPS) (of Rs.10/- each ) (not annualised)</b>				
	Basic / Diluted EPS	<b>(4.46)</b>	<b>(2.28)</b>	<b>(10.82)</b>	<b>(18.25)</b>



**TRIOCHEM PRODUCTS LIMITED****MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS**Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001.Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mail: [info@amphray.com](mailto:info@amphray.com)Website: [www.triochemproducts.com](http://www.triochemproducts.com) Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED	
<b>Notes:</b>	
1)	The above unaudited financial results of the Company for the quarter ended June 30, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 14.08.2021.
2)	The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3)	The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant
4)	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
5)	The figure for quarter ended 31st March, 2021 are the balancing figures between audited figures of the full financial year 31st March, 2021 and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
6)	The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
7)	The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
8)	The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> <p>Place: Mumbai</p> <p>Dated: 14th August, 2021</p> </div> <div style="text-align: center;"> </div> <div style="text-align: right;"> <p><b>FOR TRIOCHEM PRODUCTS LIMITED</b></p> <p></p> <p><b>RAMU S. DEORA,</b></p> <p><b>DIRECTOR &amp; CEO</b></p> <p><b>DIN: 00312369</b></p> </div> </div>	





**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS


Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED					
Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001					
website: www.triochemproducts.com					
CIN: L24249MH1972PLC015544					
(Rs. in lakhs) Except EPS					
EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021					
Sr No	Particulars	For the Quarter Ended on 30-Jun-21 Audited	For the Quarter Ended on 31-Mar-21 Unaudited	For the Quarter Ended on 30-Jun-20 Unaudited	For the Year Ended on 31-Mar-21 Audited
1	Total Income from operations	18.19	781.02	1.30	1,407.22
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(15.21)	(6.04)	(35.31)	(58.11)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(15.21)	(6.04)	(35.31)	(58.11)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(10.93)	(5.59)	(26.50)	(44.70)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1.26	(1.36)	0.09	(1.75)
6	Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50
7	Other Equity				1,146.69
8	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)				
	a) Basic (not annualized)	(4.46)	(2.28)	(10.82)	(18.25)
	b) Diluted (not annualized)	(4.46)	(2.28)	(10.82)	(18.25)
Notes:					
1) The above unaudited financial results of the Company for the quarter ended June 30, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 14.08.2021.					
2) The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).					
3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant.					
4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.					
5) The figure for quarter ended 31st March, 2021 are the balancing figures between audited figures of the full financial year 31st March, 2021 and the reviewed year-to-date figures up to the third quarter of the relevant financial year.					
6) The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.					
7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.					
8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.					
9) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website www.bseindia.com and on the Company's website www.triochemproducts.com					
Place: Mumbai		FOR TRIOCHEM PRODUCTS LIMITED			
Dated: 14th August, 2021		 RAMU S. DEORA DIRECTOR & CEO DIN: 00312369			



**Date & Time of Download : 14/08/2021 15:10:15**

**BSE ACKNOWLEDGEMENT**

<b>Acknowledgement Number</b>	3092589
<b>Date and Time of Submission</b>	8/14/2021 3:10:07 PM
<b>Scripcode and Company Name</b>	512101 - TRIOCHEM PRODUCTS LTD.
<b>Subject / Compliance Regulation</b>	Submission Of Unaudited Financial Results For The Quarter Ended 30Th June 2021
<b>Submitted By</b>	Puran Jaykisan Parmar
<b>Designation</b>	Designated Officer for Filing

**Disclaimer** : - Contents of filings has not been verified at the time of submission.

**BSE LTD**  
**ACKNOWLEDGEMENT**

Acknowledgement No	: 1408202103043633	Date & Time	: 14/08/2021 03:04:36 PM
Scrip Code	: 512101		
Entity Name	: Triochem Products Limited		
Compliance Type	: Regulation 33 - Financial Results		
Quarter / Period	: 30/06/2021		
Mode	: E-Filing		

General information about company	
Scrip code	512101
NSE Symbol	
MSEI Symbol	
ISIN*	INE331E01013
Name of company	Triochem Products Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2021
Date of end of financial year	31-03-2022
Date of board meeting when results were approved	14-08-2021
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	06-08-2021
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
Start date and time of board meeting	14-08-2021 14:00
End date and time of board meeting	14-08-2021 14:40
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable



Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2021	01-04-2021
B	Date of end of reporting period	30-06-2021	30-06-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	0	0
	Other income	18.187	18.187
	<b>Total income</b>	<b>18.187</b>	<b>18.187</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	11.498	11.498
(e)	Finance costs	0.382	0.382
(f)	Depreciation, depletion and amortisation expense	2.954	2.954
<b>(f)</b>	<b>Other Expenses</b>		
1	Other Expenses	18.559	18.559
10			
	<b>Total other expenses</b>	<b>18.559</b>	<b>18.559</b>
	<b>Total expenses</b>	<b>33.393</b>	<b>33.393</b>

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2021	01-04-2021
B	Date of end of reporting period	30-06-2021	30-06-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
3	<b>Total profit before exceptional items and tax</b>	-15.206	-15.206
4	Exceptional items	0	0
5	<b>Total profit before tax</b>	-15.206	-15.206
7	<b>Tax expense</b>		
8	Current tax	-0.217	-0.217
9	Deferred tax	-4.06	-4.06
10	<b>Total tax expenses</b>	-4.277	-4.277
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	<b>Net Profit Loss for the period from continuing operations</b>	-10.929	-10.929
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	<b>Total profit (loss) for period</b>	-10.929	-10.929

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2021	01-04-2021
B	Date of end of reporting period	30-06-2021	30-06-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	0	0
3 Amount of items that will be reclassified to profit and loss			
1	Items that will not be reclassified to profit or Loss	1.681	1.681
2	Income tax relating to items that will not be reclassified to profit or loss	-0.423	-0.423
	Total Amount of items that will be reclassified to profit and loss	1.258	1.258
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	1.258	1.258



Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2021	01-04-2021
B	Date of end of reporting period	30-06-2021	30-06-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
23	<b>Total Comprehensive Income for the period</b>	-9.671	-9.671
24	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	<b>Details of equity share capital</b>		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
27	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
29	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	-4.46	-4.46
	Diluted earnings (loss) per share from continuing operations	-4.46	-4.46
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	-4.46	-4.46
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	-4.46	-4.46
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

Text Block	
Textual Information(1)	<p>1) The above unaudited financial results of the Company for the quarter ended June 30, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 14.08.2021.</p> <p>2) The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).</p> <p>3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant</p> <p>4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.</p> <p>5) The figure for quarter ended 31st March, 2021 are the balancing figures between audited figures of the full financial year 31st March, 2021 and the reviewed year-to-date figures up to the third quarter of the relevant financial year.</p> <p>6) The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant &amp; equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.</p> <p>7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.</p> <p>8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.</p>

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2021	01-04-2021
Date of end of reporting period		30-06-2021	30-06-2021
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
	Total Segment Asset		
	Un-allocable Assets		
	Net Segment Asset		
4	Segment Liabilities		
	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		
	Disclosure of notes on segments		



